Researchers have tested a new "neoantigen" vaccine in patients with Lynch syndrome, an inherited disease that increases the risk of cancer. The vaccine has demonstrated safety and the ability to induce an immune response in test subjects. Lynch syndrome is a genetic disorder that increases the risk of various types of cancer, especially colon cancer. This preventive vaccine represents a new approach to protect people with a hereditary risk of cancer from developing the disease. The results of a study published in the journal Nature Medicine suggest the potential of personalized vaccines to prevent cancer in people with a genetic predisposition. Such vaccines could help save the lives of people with a high hereditary risk of cancer in the future.